Results 161 to 170 of about 21,037 (302)

Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis [PDF]

, 2004
Kenneth Ouriel, Alan F. Kaul, Mandy C. Leonard   +2 more
openalex   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Antinuclear and antiphospholipid autoantibodies in patients with peripheral arterial occlusive disease [PDF]

, 2004
Knut Kroeger
openalex   +1 more source

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, EarlyView.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Peripheral Arterial Occlusive Disease in Kimura's Disease: A Case Report and Literature Reviews. [PDF]

Interv Radiol (Higashimatsuyama)
Kugimiya A, Yamamoto M, Kondo H.
europepmc   +1 more source

Raised Plasma Soluble P-Selectin in Peripheral Arterial Occlusive Disease Enhances Leukocyte Adhesion [PDF]

, 2005
Kevin Woollard, D. Kling, Sarang Kulkarni, Anthony M. Dart, Shaun P. Jackson, Jaye Chin‐Dusting   +5 more
openalex   +1 more source

Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited‐Stage Small‐Cell Lung Cancer in the Phase 3 ADRIATIC Trial

Cancer Science, EarlyView.
This Japan subgroup analysis of the global phase 3 ADRIATIC trial showed that consolidation durvalumab versus placebo improves outcomes, and is well tolerated, in patients with limited‐stage small‐cell lung cancer following concurrent chemoradiotherapy comprising cisplatin or carboplatin‐based chemotherapy and once‐daily or twice‐daily radiotherapy ...
Yoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, Koichi Azuma, Kyoichi Okishio, Hirokazu Ogino, Yoshitsugu Horio, Satoshi Oizumi, Manabu Hayama, Masahiro Nii, Masaya Harada, Helen Mann, Yuka S. Olivo, Haiyi Jiang, Suresh Senan   +14 more
wiley   +1 more source

The Hemobahn endoprosthesis: A self-expanding polytetrafluoroethylene-covered endoprosthesis for the treatment of peripheral arterial occlusive disease after balloon angioplasty

, 2001
Brian G. Rubin, Gregorio A. Sicard
openalex   +1 more source

Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia [PDF]

, 2005
Karsten Lenk, Volker Adams, Philipp Lurz, Sandra Erbs, Axel Linke, Stephan Gielen, Andrej Schmidt, Dierck Scheinert, G. Biamino, Frank Emmrich, Gerhard Schüler, Rainer Hambrecht   +11 more
openalex   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, EarlyView.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source